Napo, Salix gastrointestinal news
Napo said the Supreme Court of the State of New York for the County of New York has scheduled a trial for Feb. 10, 2014, to hear a breach of contract suit Napo filed in 2011 against Salix. Napo is alleging that Salix breached a 2008 deal by "unnecessarily stalling the advancement" of diarrhea drug crofelemer and is seeking damages. The deal gave Salix rights to crofelemer in North America, Japan and Europe, excluding Liechtenstein, Norway and Switzerland. Salix said Napo's allegations are "without merit" and is moving forward with its commercialization plan for crofelemer under the terms of the deal. Salix markets the product as Fulyzaq in the U.S. to treat non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy. FDA approved Fulyzaq in December 2012 (see BioCentury, May 16, 2011; Nov. 21, 2011; Dec. 19, 2011 & Jan. 7, 2013). ...